Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation.
BACKGROUND
During the time of lowest white blood cell count (nadir) of allogeneic hematopoietic stem cell transplantation (allo-HSCT), cancer patients suffer from tremendous symptom burden related to therapy that requires intensive patient care. However, the mechanism underlying the development of multiple symptoms has not been established.


METHODS
To explore the role of inflammatory cytokines in the development of treatment-related symptoms, we studied dynamic changes in symptoms and in serum concentrations of inflammatory cytokines (interleukin [IL]-6, IL-8, soluble tumor necrosis factor receptor 1 [sTNF-R1], IL-1 receptor antagonist, and IL-12p40p70) from pretherapy throughout the first 30 days of allo-HSCT in 30 patients with acute myelogenous leukemia or myelodysplastic syndrome. We measured multiple symptoms repeatedly using the M. D. Anderson Symptom Inventory. Mixed-effects modeling was used to analyze longitudinal data.


RESULTS
In response to conditioning and stem-cell infusion, serum levels of IL-6 and the severity of multiple symptoms increased rapidly and peaked at nadir. From baseline to nadir (approximately Day 8 post-transplantation), increase in IL-6 was significantly associated with worsening of the most severe symptoms (fatigue, poor appetite, pain, drowsiness, dry mouth, and disturbed sleep; P< .01). During the first 30 days after transplantation, increases in IL-6 (P< .001) and sTNF-R1 (P< .05) significantly predicted the increasing severity of these symptoms.


CONCLUSIONS
These results suggest that release of systemic inflammatory cytokines, mainly IL-6, corresponds to an increase in treatment-related multiple-symptom burden during the nadir period of allo-HSCT.
Wang
Xin Shelley
XS
Department of Symptom Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. xswang@mdanderson.org
Shi
Qiuling
Q
Williams
Lori A
LA
Cleeland
Charles S
CS
Mobley
Gary M
GM
Reuben
James M
JM
Lee
Bang-Ning
BN
Giralt
Sergio A
SA
D015415:Biomarkers / Q000097:blood; D016207:Cytokines / Q000097:blood; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous
D015415:Biomarkers; D016207:Cytokines; D015850:Interleukin-6
Bone Marrow Transplant. 1991 Apr;7(4):311-6
2070138
Neuroimmunomodulation. 2004;11(5):279-92
15316238
Pain. 1995 Apr;61(1):69-79
7644251
Cancer Nurs. 1996 Jun;19(3):170-6
8674025
Blood. 2004 Oct 1;104(7):2194-200
15198954
Oncol Nurs Forum. 1999 Apr;26(3):575-82
10214598
Eur J Cancer. 1995;31A(2):163-73
7718320
Ann N Y Acad Sci. 1995 Dec 29;770:227-36
8597363
J Clin Oncol. 2008 Feb 20;26(6):971-82
18281672
Bone Marrow Transplant. 1995 Jan;15(1):99-104
7742764
Bone Marrow Transplant. 2005 Nov;36(9):771-9
16113665
Eur J Cancer Care (Engl). 2001 Jun;10(2):124-30
11829045
Cancer. 2003 Jun 1;97(11):2919-25
12767108
Cancer. 2000 Oct 1;89(7):1634-46
11013380
Stat Methods Med Res. 1992;1(3):225-47
1341659
Clin Cancer Res. 2003 Oct 15;9(13):4653-65
14581334
Blood. 1994 Apr 15;83(8):2360-7
8161803
Oncol Nurs Forum. 2006 May 03;33(3):535-42
16676010
Am J Hematol. 2007 Jan;82(1):45-52
16937391
Curr Opin Immunol. 1993 Oct;5(5):794-9
8240742
Oncologist. 2007;12 Suppl 1:22-34
17573453
Cytokine. 2004 Feb 7;25(3):94-102
14698135
J Immunol Methods. 1992 Aug 30;153(1-2):115-24
1381403
Brain Behav Immun. 2003 Feb;17 Suppl 1:S112-8
12615196
Semin Oncol Nurs. 1994 Feb;10(1):42-57
8165378
N Engl J Med. 1991 Mar 7;324(10):667-74
1994250
Trends Immunol. 2006 Jan;27(1):24-31
16316783
Med Sci Monit. 2002 May;8(5):HY1-9
12011758
J Natl Cancer Inst Monogr. 2007;(37):16-21
17951226
Blood. 1990 Feb 15;75(4):1011-6
2405918
Exp Hematol. 2001 Mar;29(3):259-77
11274753
Brain Behav Immun. 2007 May;21(4):413-27
17178209
Eur J Haematol. 2006 Feb;76(2):93-101
16405429
Cancer. 2006 Jun 1;106(11):2437-44
16615096
Cancer. 2001 Sep 15;92(6 Suppl):1684-8
11598887
Biol Blood Marrow Transplant. 2005 Sep;11(9):706-12
16125641
Br J Cancer. 1995 Jun;71(6):1322-9
7779732
Biochem Biophys Res Commun. 2002 Oct 4;297(4):700-13
12359210
Bone Marrow Transplant. 1996 Jun;17(6):1133-42
8807126
J Clin Oncol. 2006 Apr 20;24(12):1852-9
16622259
JAMA. 2004 May 19;291(19):2335-43
15150205